Here, we prospectively assess changes in circulating Ang-1, Ang-2, PLGF, and VEGF as a result of definitive chemo-radiotherapy in HNSCC patients, and identify tumor- and treatment-specific trends that could aid in developing future combination regimens. The gene discussed is PGF; the disease is neoplasm.